<HashMap><database>biostudies-literature</database><scores/><additional><submitter>de Zelicourt A</submitter><funding>Agence Nationale de la Recherche</funding><funding>NIA NIH HHS</funding><funding>Foundation for the National Institutes of Health</funding><funding>Fondation de France</funding><pagination>e12860</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9081905</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(5)</volume><pubmed_abstract>Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration. Two important deleterious features are a Ca&lt;sup>2+&lt;/sup> dysregulation linked to Ca&lt;sup>2+&lt;/sup> influxes associated with ryanodine receptor hyperactivation, and a muscular nicotinamide adenine dinucleotide (NAD&lt;sup>+&lt;/sup> ) deficit. Here, we identified that deletion in mdx mice of CD38, a NAD&lt;sup>+&lt;/sup> glycohydrolase-producing modulators of Ca&lt;sup>2+&lt;/sup> signaling, led to a fully restored heart function and structure, with skeletal muscle performance improvements, associated with a reduction in inflammation and senescence markers. Muscle NAD&lt;sup>+&lt;/sup> levels were also fully restored, while the levels of the two main products of CD38, nicotinamide and ADP-ribose, were reduced, in heart, diaphragm,</pubmed_abstract><journal>EMBO molecular medicine</journal><pubmed_title>CD38-NADase is a new major contributor to Duchenne muscular dystrophic phenotype.</pubmed_title><pmcid>PMC9081905</pmcid><funding_grant_id>ANR‐10‐LABX‐33</funding_grant_id><funding_grant_id>R01 AG058812</funding_grant_id><funding_grant_id>AG58812</funding_grant_id><funding_grant_id>ANR‐19‐CE14‐0031‐01</funding_grant_id><funding_grant_id>NAD‐Heart # 17‐CE17‐0015‐01</funding_grant_id><funding_grant_id>00086505</funding_grant_id><funding_grant_id>ANR‐13‐BSV1‐0023‐01</funding_grant_id><pubmed_authors>Dakouane-Giudicelli M</pubmed_authors><pubmed_authors>Pietri-Rouxel F</pubmed_authors><pubmed_authors>Bonay M</pubmed_authors><pubmed_authors>Piquereau J</pubmed_authors><pubmed_authors>Chini EN</pubmed_authors><pubmed_authors>Lefebvre F</pubmed_authors><pubmed_authors>Chini CCS</pubmed_authors><pubmed_authors>Fogarty MJ</pubmed_authors><pubmed_authors>Cancela JM</pubmed_authors><pubmed_authors>Forand A</pubmed_authors><pubmed_authors>De Jesus I</pubmed_authors><pubmed_authors>Brisebard E</pubmed_authors><pubmed_authors>Mericskay M</pubmed_authors><pubmed_authors>Launay JM</pubmed_authors><pubmed_authors>Tarrago MG</pubmed_authors><pubmed_authors>Karoui A</pubmed_authors><pubmed_authors>Zarrouki F</pubmed_authors><pubmed_authors>Sieck GC</pubmed_authors><pubmed_authors>de la Porte S</pubmed_authors><pubmed_authors>Kashyap S</pubmed_authors><pubmed_authors>Mansart A</pubmed_authors><pubmed_authors>Moog S</pubmed_authors><pubmed_authors>de Zelicourt A</pubmed_authors><pubmed_authors>Gomez AM</pubmed_authors><pubmed_authors>Fayssoil A</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD38-NADase is a new major contributor to Duchenne muscular dystrophic phenotype.</name><description>Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration. Two important deleterious features are a Ca&lt;sup>2+&lt;/sup> dysregulation linked to Ca&lt;sup>2+&lt;/sup> influxes associated with ryanodine receptor hyperactivation, and a muscular nicotinamide adenine dinucleotide (NAD&lt;sup>+&lt;/sup> ) deficit. Here, we identified that deletion in mdx mice of CD38, a NAD&lt;sup>+&lt;/sup> glycohydrolase-producing modulators of Ca&lt;sup>2+&lt;/sup> signaling, led to a fully restored heart function and structure, with skeletal muscle performance improvements, associated with a reduction in inflammation and senescence markers. Muscle NAD&lt;sup>+&lt;/sup> levels were also fully restored, while the levels of the two main products of CD38, nicotinamide and ADP-ribose, were reduced, in heart, diaphragm,</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2025-04-19T12:09:13.824Z</modification><creation>2025-02-19T00:55:35.589Z</creation></dates><accession>S-EPMC9081905</accession><cross_references><pubmed>35298089</pubmed><doi>10.15252/emmm.202012860</doi></cross_references></HashMap>